191 related articles for article (PubMed ID: 32338534)
1. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy.
Patil PA; Zhang X
Arch Pathol Lab Med; 2021 May; 145(5):571-582. PubMed ID: 32338534
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease.
Irshaid L; Robert ME; Zhang X
Arch Pathol Lab Med; 2021 Feb; 145(2):191-200. PubMed ID: 33501492
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
[TBL] [Abstract][Full Text] [Related]
4. Histopathology of Gastrointestinal Immune-related Adverse Events: A Practical Review for the Practicing Pathologist.
Zhang ML; Deshpande V
Am J Surg Pathol; 2022 Jan; 46(1):e15-e26. PubMed ID: 33999556
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.
Lo YC; Price C; Blenman K; Patil P; Zhang X; Robert ME
Am J Clin Pathol; 2021 Jul; 156(2):214-228. PubMed ID: 33555016
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations.
Williams KC; Gault A; Anderson AE; Stewart CJ; Lamb CA; Speight RA; Rajan N; Plummer R; Pratt AG
Front Immunol; 2023; 14():1122430. PubMed ID: 36776862
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.
Zen Y; Chen YY; Jeng YM; Tsai HW; Yeh MM
Histopathology; 2020 Feb; 76(3):470-480. PubMed ID: 31550390
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic Manifestations of Immune Checkpoint Inhibitor Therapy-Associated Gastrointestinal Tract Injury: A Practical Review.
Mitchell JM; Karamchandani DM
Surg Pathol Clin; 2023 Dec; 16(4):703-718. PubMed ID: 37863561
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
Cramer P; Bresalier RS
Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Assarzadegan N; Montgomery E; Anders RA
Virchows Arch; 2018 Jan; 472(1):125-133. PubMed ID: 29143108
[TBL] [Abstract][Full Text] [Related]
12. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective.
Karamchandani DM; Chetty R
J Clin Pathol; 2018 Aug; 71(8):665-671. PubMed ID: 29703758
[TBL] [Abstract][Full Text] [Related]
14. Upper gastrointestinal tract involvement of pediatric inflammatory bowel disease: A pathological review.
Abuquteish D; Putra J
World J Gastroenterol; 2019 Apr; 25(16):1928-1935. PubMed ID: 31086461
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis.
Khan J; Katona T
Cureus; 2021 Sep; 13(9):e18085. PubMed ID: 34692300
[TBL] [Abstract][Full Text] [Related]
16. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry.
Placke JM; Rawitzer J; Reis H; Rashidi-Alavijeh J; Livingstone E; Ugurel S; Hadaschik E; Griewank K; Schmid KW; Schadendorf D; Roesch A; Zimmer L
Front Oncol; 2021; 11():725549. PubMed ID: 34458154
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-associated celiac disease.
Badran YR; Shih A; Leet D; Mooradian MJ; Coromilas A; Chen J; Kem M; Zheng H; Borowsky J; Misdraji J; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581063
[TBL] [Abstract][Full Text] [Related]
19. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.
Lo Preiato V; Salvagni S; Ricci C; Ardizzoni A; Pagotto U; Pelusi C
Rev Endocr Metab Disord; 2021 Jun; 22(2):337-349. PubMed ID: 33409866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
